Loading…
← CockpitCompetitor Analysis › BCRX BioCryst Pharmaceuticals, Inc.Open in the cockpit ↗

BioCryst Pharmaceuticals, Inc.BCRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.

Momentum weak 27
Mkt cap
$1.88B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$40.8M
20-day average traded
Fwd P/E
11.1×
forward earnings
ROIC−WACC
n/a
WACC 7.1%
Hurdle
-129 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · USD$7.30
1D-2.7%
1W-4.6%
1M-8.1%
3M-24.4%
6M-16.5%
YTD-6.4%
1Y+3.8%
ATR %4.6%
Beta0.66
52w lowhigh34.9% off high

What BioCryst Pharmaceuticals does

Develops and sells oral therapies for rare diseases, led by Orladeyo for hereditary angioedema prevention.

Orladeyo, a capsule taken daily to prevent attacks, is the revenue base; it is sold mainly in the US through specialty pharmacies, with overseas partners selling in some markets. Because patients stay on it for years, revenue recurs, and some proceeds are owed to outside royalty holders from earlier financing.

Products and services

  • Orladeyo (HAE prophylaxis)
  • Rare disease pipeline in complement/PNH

Customers

  • Allergists/immunologists
  • HAE patients

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Rare disease therapeutics

What could go right

  • Orladeyo revenue growth
  • Pipeline diversification

What could go wrong

  • Competitive oral HAE entrants
  • Patent and exclusivity risk

Moat: narrow (regulatory licence, IP / patents). Approved oral HAE prophylaxis with growing sales, though competing against injectable alternatives.

Headquarters: Durham, North Carolina, US · Founded: 1986 · Employees: 435

Named competitors

BioCryst Pharmaceuticals at a glance

Size BioCryst Pharmaceuticals (BCRX) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1807th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.30 on 18 Nov 2026.

Performance Over six months the shares fell 16.5%, against -3.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue grew 60.3% over the last twelve months (peer median +5.5%); the operating margin is 42.5% (peer median -58.6%).

Valuation It trades at 11.1× forward earnings against a peer median of 51.9× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +118%, so the hurdle is -129 pp: the price already allows for a slowdown.

Short interest Short interest is 10.7% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 97BCRX 87
Six months, rebased to 100: BioCryst Pharmaceuticals against the median of its 20 peers (local-currency closes).

BioCryst Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$962M$875M$451M$331M$271M
Revenue growth—+94%+36%+22%—
Gross profit$939M$854M$437M$325M$263M
EBITDA$411M$342M-$1.30M-$102M-$147M
Net income-$360M$264M-$88.9M-$227M-$247M
Free cash flow$349M$327M-$53.1M-$97.3M-$163M
Capital expenditure$1.65M$2.47M$1.12M$2.17M$1.35M
Total debt$828M$477M$841M$849M$741M

Quarterly statements and history in the cockpit →

BioCryst Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%REPLSEPNTRAX300601688520VERAMRVITRVICOAGZBIORXRXSTOKALMRBCRX6-month return →1-month return →
Up and to the right = strong over both horizons. BioCryst Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%50×100×300601688046AUPH145020300676BCRXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. BioCryst Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300601688046AUPH145020BCRXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. BioCryst Pharmaceuticals is the large dot.

BioCryst Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (BCRX vs PHVS vs 4502.T vs IONS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
BioCryst Pharmaceuticals BCRX$1.88B-16%+60%42%11.1×-11.0%
Pharvaris PHVS$2.21B+7%n/an/an/an/a
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%n/an/a
Intellia Therapeutics NTLA$1.37B-20%-8%-821%n/an/a
Pharming PHARM.AS$867M-6%+2%9%34.9×2.4%

How BioCryst Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

BioCryst Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureBCRXPeer medianRank in peer set
1-month return-8.1%-1.1%7th lowest of 20
6-month return-16.5%-3.6%6th lowest of 19
Distance from 52-week high-34.9%-33.4%10th lowest of 21
Revenue growth (TTM)+60.3%+5.5%3rd highest of 15
Operating margin42.5%-58.6%2nd highest of 15
Forward P/E11.1×51.9×cheapest of 6
Growth the price implies (Req g, 7 yrs)-11.0%13.1%2nd least demanding of 5
Growth delivered (Del g)+117.9%+19.9%highest of 5
Hurdle (Req g minus delivered)-128.9 pp-9.5 ppleast demanding of 5
EV / EBITDA5.7×n/a—
Net debt / EBITDA1.1×-2.6×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%105.5×22.7%+3.4%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%n/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%18.1×3.5%+41.4%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/an/an/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%n/an/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%126.7×n/an/a

Questions

Who are BioCryst Pharmaceuticals's main competitors?
Named competitors: Pharvaris (PHVS), CSL Behring (private or unlisted), KalVista Pharmaceuticals (private or unlisted), Takeda Pharmaceutical (4502.T), Ionis Pharmaceuticals (IONS), Intellia Therapeutics (NTLA). The cockpit's measured peer set (industry) also includes Replimune (REPL), Septerna (SEPN), First Tracks Biotherapeutics (TRAX), Shenzhen Kangtai Biological Products (300601.SZ), Sinocelltech (688520.SS), Vera Therapeutics (VERA).
Is BioCryst Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 11.1× against a peer median of 51.9×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +118%, so the hurdle is -129 pp: the price already allows for a slowdown.
How has BioCryst Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -16.5% against -3.6% for the median peer; over one year +3.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.